Hypothesis

Baseline pain sensitivity reflects mitochondrial redox state and autonomic balance, such that a brief quantitative sensory test (QST) combined with heart‑rate variability (HRV) and circulating cell‑free mitochondrial DNA (cf‑mtDNA) predicts epigenetic age acceleration more accurately than current standalone clocks.

Mechanistic Basis

Chronic low‑grade nociceptor activity sustains tonic calcium influx through TRPV1 channels, driving mitochondrial NADPH oxidase (NOX2) derived superoxide production. Elevated mitochondrial ROS activates the NLRP3 inflammasome in peripheral immune cells, increasing IL‑1β release and promoting NAD+ consumption. Reduced NAD+ diminishes SIRT3 deacetylase activity, leading to hyper‑acetylated, inefficient electron‑transport‑chain complexes and further ROS leak—a vicious loop that mirrors the inflammaging‑driven shifts captured by DNAmGrimAge and DNAmPhenoAge. Concurrently, heightened sympathetic tone lowers HRV, while parasympathetic withdrawal reduces vagal anti‑inflammatory signaling, reinforcing the nociceptor‑mitochondria axis.

Testable Predictions

1. Individuals with lower heat and pressure pain thresholds will exhibit higher baseline cf‑mtDNA concentrations and lower HRV (RMSSD) after adjusting for age, sex, and BMI.
2. The composite index (pain threshold score × HRV⁻¹ × cf‑mtDNA) will show a stronger negative correlation with DNAmPhenoAge (r < −0.60) than either pain threshold or HRV alone.
3. Intervention that boosts mitochondrial NAD+ (e.g., NR supplementation) will increase pain thresholds, raise HRV, and reduce cf‑mtDNA, concomitant with a measurable slowing of epigenetic age change over 6 months.

Experimental Design

• Recruit 200 adults aged 40‑70, stratify by self‑reported pain status (none, mild, chronic).
• At baseline assess: (a) quantitative sensory testing (heat pain threshold, pressure pain threshold), (b) 5‑minute resting HRV (RMSSD), (c) plasma cf‑mtDNA via qPCR, (d) epigenetic age using DNAmPhenoAge.
• Follow participants for 12 months with quarterly pain QST and HRV; collect cf‑mtDNA and epigenetic age at 6‑ and 12‑month visits.
• Randomly assign a subset (n = 60) to receive NR 500 mg daily vs placebo for 6 months; assess changes in the composite index and epigenetic age drift.

Potential Impact

If validated, a 10‑minute bedside pain‑sensitivity protocol augmented by wearable HRV and a simple blood cf‑mtDNA assay could serve as a low‑cost, dynamic biomarker of biological age, enabling early detection of inflammaging and personalized longevity interventions without reliance on expensive epigenetic profiling.